MedDataX Logo

Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects

NCT ID: NCT06119958

Last Updated: 2023-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-27

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is A two-arm, open-label, single-sequence, multiple oral dosings, crossover study to evaluate the safety and the pharmacokinetic interaction of DWC202313 and DWC202314 in healthy adult volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20161 in Healthy Volunteers

NCT02947139

Healthy
COMPLETED PHASE1

Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20163 in Healthy Volunteers

NCT03005223

Healthy
UNKNOWN PHASE1

Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20162 in Healthy Volunteers

NCT02952755

Healthy
COMPLETED PHASE1

Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects

NCT05699070

Drug-drug Interaction
UNKNOWN PHASE1

Study to Explore Drug-drug Interactions Between DWC20155 and DWC20156 in Healthy Subjects

NCT02704559

Healthy
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Drug Interaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DWC202313

DWC202313

Group Type EXPERIMENTAL

DWC202313

Intervention Type DRUG

Experimental Drug 1

DWC202314

DWC202314

Group Type EXPERIMENTAL

DWC202314

Intervention Type DRUG

Experimental Drug 2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DWC202313

Experimental Drug 1

Intervention Type DRUG

DWC202314

Experimental Drug 2

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* over 19 year old

Exclusion Criteria

* Galactose intolerance
* Lapp lactase deficiency
Minimum Eligible Age

19 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

H Plus YANGJI Hospital

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Seung-Hyun Kang, MD, Ph D

Role: CONTACT

[email protected]
070-4665-9490

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Seung-Hyun Kang, MD, Ph D.

Role: primary

[email protected]
070-4665-9490

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DWJ1622101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults
NCT07213310 NOT_YET_RECRUITING PHASE1
The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults
NCT05321732 UNKNOWN PHASE1
Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults
NCT06644404 NOT_YET_RECRUITING PHASE1
Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects
NCT05574374 COMPLETED PHASE1
Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults
NCT05500898 UNKNOWN PHASE1
Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male Adults
NCT04343547 UNKNOWN PHASE1
Phase 1 Study of DDI Between DW330SR and DW1030 in Healthy Male Subjects
NCT02071381 COMPLETED PHASE1
Drug-drug Interaction Study Between UIC201603, and UIC201604
NCT06568133 COMPLETED PHASE1
Drug-drug Interaction Study Between UIC201601 and UIC201602
NCT05190133 COMPLETED PHASE1
A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers
NCT05009368 COMPLETED PHASE1
Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects
NCT05106205 COMPLETED PHASE1
Phase 1 Study of DW-0919 & DW-0920 in Healthy Male Volunteers Under Fasting Condition
NCT01606059 COMPLETED PHASE1
A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants
NCT05994807 COMPLETED PHASE1
Pharmacokinetics and Safety of DWJ1451 in Healthy Adults
NCT04819932 UNKNOWN PHASE1
Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed State
NCT05098275 COMPLETED PHASE1
Drug-drug Interaction Study (CKD-501, Ketoconazole)
NCT01330563 COMPLETED PHASE1
Dicloxacillin: Clinical Relevance of Drug-drug Interactions by Induction of Drug Metabolism.
NCT02983890 COMPLETED PHASE1
Investigating the Pharmacokinetic Drug Interactions Between HGP1201 and HGP0904
NCT02243319 COMPLETED PHASE1
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150
NCT04334213 COMPLETED PHASE1
Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State
NCT05098262 COMPLETED PHASE1
A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects
NCT03726866 UNKNOWN PHASE1
A Phase 1 Drug Drug Interaction Clinical Trial of C1-R215 and C2-R215 in Healthy Male Volunteers
NCT03005340 UNKNOWN PHASE1
Dabigatran in an Interaction Probe Drug Cocktail
NCT02361619 COMPLETED PHASE1
Drug-Drug Interaction Study in Healthy Adult Volunteers
NCT02276001 COMPLETED PHASE1
Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects
NCT01332890 COMPLETED PHASE1